Drug Profile

APC 2059

Latest Information Update: 02 Jul 2004

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer; Celera Genomics Group
Developer Celera Genomics Group
Class Anti-inflammatories; Dioxoles; Guanidines; Small molecules
Mechanism of Action Peptide hydrolase inhibitors; Tryptase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Inflammatory bowel diseases; Psoriasis; Ulcerative colitis

Most Recent Events

06 Jun 2004 Discontinued - Phase-I for Inflammatory bowel disease in USA (IV-injection)
06 Jun 2004 Discontinued - Phase-II for Ulcerative colitis in USA (SC)
30 Mar 2001 Clinical trials of APC 2059 in asthma postponed until 2002

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com